<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03687970</url>
  </required_header>
  <id_info>
    <org_study_id>201807162</org_study_id>
    <secondary_id>1R43CA206796-01A1</secondary_id>
    <nct_id>NCT03687970</nct_id>
  </id_info>
  <brief_title>A New Method for Identifying Sensory Changes in Painful Chemotherapy-induced Peripheral Neuropathy (CIPN)</brief_title>
  <official_title>A New Method for Identifying Sensory Changes in Painful Chemotherapy-induced Peripheral Neuropathy (CIPN): a Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>LasMed LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose that using the Diode Laser fiber type Selective Stimulator (DLss)&#xD;
      in patients with chemotherapy-induced peripheral neuropathy (CIPN) will allow for the&#xD;
      assessment of changes in small-fiber pain thresholds, to identify differences between&#xD;
      subjects who received chemotherapy and developed painful CIPN, compared to subjects who&#xD;
      received similar chemotherapy but did not develop painful CIPN (control group).&#xD;
&#xD;
      Additionally, the investigators would like to investigate whether the response to DLss&#xD;
      correlates with pain severity in patients with persistent painful neuropathy.&#xD;
&#xD;
      The ultimate goal of this study is to develop a non-invasive, bedside quantitative test that&#xD;
      is specific for painful CIPN. If the investigators' initial hypothesis is confirmed, the next&#xD;
      step would be to design a prospective longitudinal study and assess changes in DLss early&#xD;
      after initiation of chemotherapy, to determine whether this approach can help identify early&#xD;
      predictive parameters of painful CIPN.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Painful chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of&#xD;
      chemotherapy, occurring in more than 60% of patients at some point during the course of&#xD;
      cancer treatment with commonly used drugs such as taxanes and platinum compounds. It&#xD;
      potentially may result in severely diminished quality of life and dose reduction or/and&#xD;
      treatment delay, which may ultimately impact survival.&#xD;
&#xD;
      The mechanisms by which chemotherapy-induced nerve damage ultimately leads to pain are poorly&#xD;
      understood, because virtually no structural or functional differences in nerve fibers between&#xD;
      painless and painful peripheral neuropathy have been identified. As a result, there is no&#xD;
      reliable way to predict which patients will develop persistent painful chemotherapy-induced&#xD;
      peripheral neuropathy.&#xD;
&#xD;
      The ultimate goal of this study is to develop a non-invasive, bedside quantitative test that&#xD;
      is specific for painful CIPN. If our initial hypothesis is confirmed, the next step would be&#xD;
      to design a prospective longitudinal study and assess changes in DLss early after initiation&#xD;
      of chemotherapy, to determine whether this approach can help identify early predictive&#xD;
      parameters of painful CIPN.&#xD;
&#xD;
      In this other interventional study, we will test the utility of the Diode Laser fiber type&#xD;
      Selective Stimulator (DLss) to identify sensory changes that are unique to patients with&#xD;
      painful chemotherapy induced peripheral neuropathy (CIPN) vs. controls.&#xD;
&#xD;
      Painful symptoms of CIPN develop in patients with differential nerve damage to Aδ vs C-type&#xD;
      peripheral nerve fibers. We hypothesize that Aδ:C fiber threshold ratio, as measured by the&#xD;
      DLss, will be different between patients with painful CIPN compared to control patients who&#xD;
      received a similar regimen of chemotherapy, but did not develop painful CIPN. The&#xD;
      confirmation of hypothesis may lead to a novel approach for early detection of CIPN.&#xD;
&#xD;
      Subjects: 20 evaluable patients with painful CIPN following treatment with oxaliplatin,&#xD;
      cisplatin, paclitaxel, docetaxel (or any combination of above) will be included in painful&#xD;
      CIPN group, and 20 controls matched by the type of chemotherapy received, who did not develop&#xD;
      painful CIPN.&#xD;
&#xD;
      The study procedure will include a one-time visit for sensory assessments including:&#xD;
&#xD;
        1. Spontaneous pain at baseline on 0-10 Numerical Rating Scale (NRS);&#xD;
&#xD;
        2. Assessment of pain symptoms on Neuropathic pain Symptom Inventory (NPSI) and Brief Pain&#xD;
           Inventory (BPI).&#xD;
&#xD;
        3. Assessment of mood on hospital anxiety and depression scale (HADS)&#xD;
&#xD;
        4. Quantitative sensory testing (QST): thermal detection and pain thresholds, mechanical&#xD;
           detection threshold, temporal summation (TS), and conditioned pain modulation (CPM).&#xD;
&#xD;
      The primary outcome is the comparison of Aδ:C fiber threshold ratio between patients who have&#xD;
      developed painful CIPN, and the control subjects.&#xD;
&#xD;
      In secondary analyses, we will generate Spearman correlation coefficient between the &quot;Aδ:C&#xD;
      fiber threshold ratio&quot; and the severity of painful CIPN on NPSI scale.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 17, 2018</start_date>
  <completion_date type="Actual">September 17, 2019</completion_date>
  <primary_completion_date type="Actual">September 17, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Aδ:C Fiber Detection Threshold Ratio</measure>
    <time_frame>At the time of the DLss (day 1)</time_frame>
    <description>Comparison of the Aδ:C fiber detection threshold ratio (as measured by the DLss) between patients with painful neuropathy and patients who did not develop painful neuropathy following similar cancer chemotherapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Aδ:C Pain Threshold Ratio</measure>
    <time_frame>At the time of the DLss (day 1)</time_frame>
    <description>Aδ:C pain threshold shows Aδ fiber threshold divided by C fiber threshold measured by DLss detection and pain threshold protocols.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Severity of Neuropathy on NPSI Scale.</measure>
    <time_frame>At the time of the DLss (day 1)</time_frame>
    <description>The severity of painful CIPN on Neuropathic Pain Symptom Inventory (NPSI) scale.&#xD;
Increased NPSI (0-100) score indicates more severe neuropathic pain.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Chemotherapy-induced Peripheral Neuropathy</condition>
  <arm_group>
    <arm_group_label>Group A: Painful CIPN Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>-Performed at baseline: NPSI, BPI, HADS, Spontaneous pain at baseline on 0-10 Numerical Rating Scale (NRS), QST, CPM, and DLss</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>-Performed at baseline: NPSI, BPI, HADS, Spontaneous pain at baseline on 0-10 Numerical Rating Scale (NRS), QST, CPM, and DLss</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Brief Pain Inventory</intervention_name>
    <description>-A self-administered questionnaire used to evaluate the severity of a patient's pain and the impact of this pain on the patient's daily functioning. The patient is asked to rate their worst, least, average, and current pain intensity (4 items which generate the PAIN SEVERITY score), list current treatments and their perceived effectiveness, and rate the degree that pain interferes with general activity, mood, walking ability, normal work, relations with other persons, sleep, and enjoyment of life (7 items which generate the PAIN INTERFERENCE score) on a 10 point scale.</description>
    <arm_group_label>Group A: Painful CIPN Group</arm_group_label>
    <arm_group_label>Group B: Control Group</arm_group_label>
    <other_name>BPI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hospital Anxiety and Depression Scale</intervention_name>
    <description>14 item scale with even of the items relating to anxiety and seven relating to depression&#xD;
Each item on the questionnaire is scored from 0-3 and this means that a patient can score between 0 and 21 for either anxiety or depression</description>
    <arm_group_label>Group A: Painful CIPN Group</arm_group_label>
    <arm_group_label>Group B: Control Group</arm_group_label>
    <other_name>HADS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Neuropathic Pain Symptom Inventory</intervention_name>
    <description>-The NPSI questionnaire utilized in this study includes eight parameters (i.e., burning pain, squeezing pain, pressure pain, electric shock pain, stabbing pain, tingling pain, pins and needles pain and allodynia [pain provoked by light touch]). Each of the parameters includes recall of the past 24 hours</description>
    <arm_group_label>Group A: Painful CIPN Group</arm_group_label>
    <arm_group_label>Group B: Control Group</arm_group_label>
    <other_name>NPSI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Diode Laser fiber type Selective Stimulator</intervention_name>
    <description>-Each patient will have an A and C fiber stimulation. Stimulation will be performed on the dorsum of the foot using stimulation previously published parameters to elicit &quot;burning pain,&quot; which is from activation of C-fibers and &quot;pinprick&quot; pain from A-fibers</description>
    <arm_group_label>Group A: Painful CIPN Group</arm_group_label>
    <arm_group_label>Group B: Control Group</arm_group_label>
    <other_name>DLss</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Quantitative sensory testing</intervention_name>
    <description>Quantitative sensory testing will be performed on the dorsal mid-foot and the ipsilateral shoulder will serve as control area&#xD;
Cold and warm detection thresholds, cold and heat pain thresholds, mechanical detection thresholds, and wind-up ratio</description>
    <arm_group_label>Group A: Painful CIPN Group</arm_group_label>
    <arm_group_label>Group B: Control Group</arm_group_label>
    <other_name>QST</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Conditioned pain modulation efficiency</intervention_name>
    <description>-Immersion of a hand up to the wrist to a thermostat-controlled water bath maintained at 12 degrees Celsius, and the application of a heat stimulus on the contralateral forearm.</description>
    <arm_group_label>Group A: Painful CIPN Group</arm_group_label>
    <arm_group_label>Group B: Control Group</arm_group_label>
    <other_name>CPM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Spontaneous pain at baseline on 0-10 Numerical Rating Scale (NRS)</intervention_name>
    <description>-The subjects are asked to rate the intensity of their current pain on a 0-10 scale - 0 denoting &quot;no pain&quot; and 10 denoting &quot;worst imaginable pain&quot;.</description>
    <arm_group_label>Group A: Painful CIPN Group</arm_group_label>
    <arm_group_label>Group B: Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Group A: Painful CIPN group&#xD;
&#xD;
          -  Age &gt;18&#xD;
&#xD;
          -  Distal symmetric pain distribution (both feet, with or without pain in hands).&#xD;
&#xD;
          -  The pain appeared during or up to 12 weeks after treatment with oxaliplatin,&#xD;
             cisplatin, paclitaxel, docetaxel or any combination of these.&#xD;
&#xD;
          -  Score of 4 or more on Douleur Neuropathique 4 (DN4) neuropathic pain questionnaire&#xD;
&#xD;
          -  Pain duration &gt; 2 months.&#xD;
&#xD;
          -  Patient report of average daily pain intensity in the last week ≥3 on 0-10 Numerical&#xD;
             Rating Scale (NRS).&#xD;
&#xD;
          -  Able and willing to sign an Institutional Review Board (IRB)-approved written informed&#xD;
             consent.&#xD;
&#xD;
        Group B: Control group:&#xD;
&#xD;
          -  Age &gt;18&#xD;
&#xD;
          -  History of cancer diagnosis, previously treated with at least 8 infusions of&#xD;
             chemotherapy regimen that included oxaliplatin or at least 6 infusions of chemotherapy&#xD;
             regimen that included cisplatin, paclitaxel, docetaxel, or any combination of these.&#xD;
&#xD;
          -  No ongoing pain in distal symmetric distribution (subjects with symptoms and signs&#xD;
             such as mild numbness, or vibration sensation loss are eligible to be included in the&#xD;
             control group).&#xD;
&#xD;
          -  Able and willing to sign an IRB-approved written informed consent. * Subjects in the&#xD;
             control group will be matched by the type of previous chemotherapy to the subjects in&#xD;
             the Painful CIPN group. An additional attempt will be made to match controls by sex,&#xD;
             age, cancer diagnosis, and cumulative neurotoxic chemotherapy dose.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of pre-existing painful distal symmetric polyneuropathy prior to chemotherapy.&#xD;
&#xD;
          -  Alternative etiology exists for the distal painful symptoms.&#xD;
&#xD;
          -  Current or previous treatment with a vinca alkaloid (e.g. vincristine, vinblastine),&#xD;
             bortezomib, or another agent which may cause major peripheral neurotoxicity.&#xD;
&#xD;
          -  Pregnant&#xD;
&#xD;
          -  Concomitant medication as follows:&#xD;
&#xD;
          -  Patients receiving chronic daily opioids, topical lidocaine or topical capsaicin will&#xD;
             be excluded.&#xD;
&#xD;
          -  Patients receiving as needed (PRN) analgesics, including acetaminophen, NSAIDs or&#xD;
             short-acting opioids, will be required not to take them 48h before testing, at for at&#xD;
             least five half-lives of the specific analgesic, at the discretion of the&#xD;
             investigators.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simon Haroutounian, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.siteman.wustl.edu</url>
    <description>Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</description>
  </link>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>September 25, 2018</study_first_submitted>
  <study_first_submitted_qc>September 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2018</study_first_posted>
  <results_first_submitted>August 29, 2020</results_first_submitted>
  <results_first_submitted_qc>September 28, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 22, 2020</results_first_posted>
  <last_update_submitted>April 28, 2021</last_update_submitted>
  <last_update_submitted_qc>April 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CIPN</keyword>
  <keyword>Neuropathic pain</keyword>
  <keyword>DLss</keyword>
  <keyword>Peripheral neuropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>In accordance with the recent proposal from the International Committee of Medical Journal Editors, patient-level data will be made available within 6 months after publication of the primary manuscript. Data will be provided to researchers who submit a methodologically sound research proposal including a protocol and statistical analysis plan. No patient-identifying fields (including dates) will be included in the shared dataset. Certain technical data related to the intellectual property rights of LasMed LLC may not be available for sharing.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Patient-level data will be made available within 6 months after publication of the primary manuscript.</ipd_time_frame>
    <ipd_access_criteria>Data will be provided to researchers who submit a methodologically sound research proposal including a protocol and statistical analysis plan. No patient-identifying fields (including dates) will be included in the shared dataset. Certain technical data related to the intellectual property rights of LasMed LLC may not be available for sharing.</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 21, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/70/NCT03687970/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 2, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/70/NCT03687970/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted at Washington University in St Louis School of Medicine. Participants were recruited between September 17, 2018, and September 17, 2019.</recruitment_details>
      <pre_assignment_details>This is a case-control study. Case group: Patients with current symptoms of painful chemotherapy-induced peripheral neuropathy (CIPN) following treatment with oxaliplatin, cisplatin, paclitaxel, or docetaxel. Control group: patients who received the same chemotherapy agents, but who did not report current (or other long-term) painful CIPN.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group A: Painful Neuropathy Group</title>
          <description>Patient with painful neuropathy after receiving treatment with oxaliplatin, cisplatin, paclitaxel or docetaxel</description>
        </group>
        <group group_id="P2">
          <title>Group B: Control Group</title>
          <description>Patient with no painful CIPN after receiving treatment with ...</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>visit scheduling conflicts</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Since this is a case-control study only patients completed the study visit are reported here.</population>
      <group_list>
        <group group_id="B1">
          <title>Group A: Painful CIPN Group</title>
          <description>Patients after chemotherapy with painful neuropathy</description>
        </group>
        <group group_id="B2">
          <title>Group B: Control Group</title>
          <description>Patients after chemotherapy without painful neuropathy</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.1" spread="10.6"/>
                    <measurement group_id="B2" value="50.5" spread="14.5"/>
                    <measurement group_id="B3" value="54.3" spread="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Aδ:C Fiber Detection Threshold Ratio</title>
        <description>Comparison of the Aδ:C fiber detection threshold ratio (as measured by the DLss) between patients with painful neuropathy and patients who did not develop painful neuropathy following similar cancer chemotherapy</description>
        <time_frame>At the time of the DLss (day 1)</time_frame>
        <population>Enrolled patients from control and case groups who completed Aδ:C fiber detection threshold ratio testing by DLss</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Painful Neuropathy Group</title>
            <description>-patients after chemotherapy with painful CIPN who completed Aδ:C fiber detection threshold ratio testing by DLss.</description>
          </group>
          <group group_id="O2">
            <title>Group B: Control Group</title>
            <description>-patients after chemotherapy who did not report current (or other long-term) painful CIPN and completed Aδ:C fiber detection threshold ratio testing by DLss.</description>
          </group>
        </group_list>
        <measure>
          <title>Aδ:C Fiber Detection Threshold Ratio</title>
          <description>Comparison of the Aδ:C fiber detection threshold ratio (as measured by the DLss) between patients with painful neuropathy and patients who did not develop painful neuropathy following similar cancer chemotherapy</description>
          <population>Enrolled patients from control and case groups who completed Aδ:C fiber detection threshold ratio testing by DLss</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.04" spread="0.74"/>
                    <measurement group_id="O2" value="1.57" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Multivariable logistic regression was applied to predict binary outcome while controlling for other potential confounding factors (age, cumulative chemotherapy dose, chemotherapy group).</non_inferiority_desc>
            <p_value>0.05</p_value>
            <p_value_desc>threshold for p value is 0.05.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Slope</param_type>
            <param_value>-0.130</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Aδ:C Pain Threshold Ratio</title>
        <description>Aδ:C pain threshold shows Aδ fiber threshold divided by C fiber threshold measured by DLss detection and pain threshold protocols.</description>
        <time_frame>At the time of the DLss (day 1)</time_frame>
        <population>Aδ:C threshold ratios were measured among patients from both groups. Only patients who finished DLss testing for pain threshold determination were included in analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Painful Neuropathy Group</title>
            <description>-patients after chemotherapy with painful CIPN who completed Aδ:C fiber detection threshold ratio testing by DLss.</description>
          </group>
          <group group_id="O2">
            <title>Group B: Control Group</title>
            <description>-patients after chemotherapy who did not report current (or other long-term) painful CIPN and completed Aδ:C fiber detection threshold ratio testing by DLss.</description>
          </group>
        </group_list>
        <measure>
          <title>The Aδ:C Pain Threshold Ratio</title>
          <description>Aδ:C pain threshold shows Aδ fiber threshold divided by C fiber threshold measured by DLss detection and pain threshold protocols.</description>
          <population>Aδ:C threshold ratios were measured among patients from both groups. Only patients who finished DLss testing for pain threshold determination were included in analysis.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.95" spread="0.71"/>
                    <measurement group_id="O2" value="1.60" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Spearman correlation coefficient between the Aδ:C fiber detection threshold ratio and the severity of painful CIPN on NPSI scale for patients with painful CIPN was calculated.</non_inferiority_desc>
            <p_value>0.7525</p_value>
            <p_value_desc>The thrshold for p value is 0.05.</p_value_desc>
            <method>Spearman's correlation coefficient</method>
            <param_type>rho coefficient</param_type>
            <param_value>0.22</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Spearman correlation coefficient between the Aδ:C fiber detection threshold ratio and the severity of painful CIPN on NPSI scale for Control group patients without painful CIPN was calculated.</non_inferiority_desc>
            <p_value>0.1876</p_value>
            <p_value_desc>The threshold for p value is 0.05.</p_value_desc>
            <method>Spearman's correlation coefficien</method>
            <param_type>rho coefficient</param_type>
            <param_value>0.32</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Spearman correlation coefficient between the Aδ:C fiber pain threshold ratio and the severity of painful CIPN on NPSI scale for patients with painful CIPN was calculated.</non_inferiority_desc>
            <p_value>0.61</p_value>
            <p_value_desc>The threshold for p value is 0.05.</p_value_desc>
            <method>Spearman's correlation coefficient</method>
            <param_type>rho coefficient</param_type>
            <param_value>0.13</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Spearman correlation coefficient between the Aδ:C fiber detection threshold ratio and the severity of painful CIPN on NPSI scale for patients with painful CIPN was calculated.</non_inferiority_desc>
            <p_value>0.2914</p_value>
            <p_value_desc>The threshold for p value is 0.05.</p_value_desc>
            <method>Spearman's correlation coefficient</method>
            <param_type>rho coefficient</param_type>
            <param_value>-0.2812205</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Severity of Neuropathy on NPSI Scale.</title>
        <description>The severity of painful CIPN on Neuropathic Pain Symptom Inventory (NPSI) scale.&#xD;
Increased NPSI (0-100) score indicates more severe neuropathic pain.</description>
        <time_frame>At the time of the DLss (day 1)</time_frame>
        <population>Only patients who completed NPSI questionnaire were included in analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Painful Neuropathy Group</title>
            <description>-patients after chemotherapy with painful CIPN who completed NPSI questionnaire were included in the analysis.</description>
          </group>
          <group group_id="O2">
            <title>Group B: Control Group</title>
            <description>-patients after chemotherapy who did not report current (or other long-term) painful CIPN and completed NPSI questionnaire were included in the analysis.</description>
          </group>
        </group_list>
        <measure>
          <title>The Severity of Neuropathy on NPSI Scale.</title>
          <description>The severity of painful CIPN on Neuropathic Pain Symptom Inventory (NPSI) scale.&#xD;
Increased NPSI (0-100) score indicates more severe neuropathic pain.</description>
          <population>Only patients who completed NPSI questionnaire were included in analysis.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.60" spread="19.89"/>
                    <measurement group_id="O2" value="0.2" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Since study activities included relatively safe testings conducted within a day the safety data were actively collected during study visit day. Patients were informed to report any adverse effects throughout the study visit day, and by telephone any time after the study visit.</time_frame>
      <desc>any unfavorable medical occurrence in a human subject including any abnormal sign, symptom, or disease.</desc>
      <group_list>
        <group group_id="E1">
          <title>Group A: Painful CIPN Group</title>
          <description>All patients who were enrolled in the Case group and completed any testing</description>
        </group>
        <group group_id="E2">
          <title>Group B: Control Group</title>
          <description>All patients who were enrolled in the Control group and completed any testing</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE version 4.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain of skin</sub_title>
                <description>increased sensitivity and pain in the right foot after testing. Duration: 30 minutes. Self-resolved.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Simon Haroutounian, PhD. Assistant Professor,</name_or_title>
      <organization>Washington University</organization>
      <phone>314-286-1715</phone>
      <email>simon.haroutounian@wustl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

